USA flag logo/image

An Official Website of the United States Government

TAS::75 0849::TAS TOPIC 255: A TARGETED DRUG FOR NON-MUSCLE INVASIVE BLADDER…

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
 Program Year/Program:
2011 / SBIR
Agency Tracking Number:
N43CO110094 		Solicitation Year:
2011 		Solicitation Topic Code:
NCI 		Solicitation Number:
Small Business Information
CELEK PHARMACEUTICALS, LLC
119 UPSHIRE CIR GAITHERSBURG, MD 20878-5215
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: TAS::75 0849::TAS TOPIC 255: A TARGETED DRUG FOR NON-MUSCLE INVASIVE BLADDER CANCER
Agency: HHS
Contract: N43CO110094
Award Amount: $176,266.00
 

Abstract:

CEL-031 is being developed as a novel, targeted tre8tment for non-mLiscle invasive bladder cancer (NMIBC). Bladder cancer is the 5th most common cancer in the US, with most cases diagnosed 8t the nonmuscle invasive stage. It is the most expensive cancerto treDt on a per patient basis. There is 8 significant need for more effective and less toxic therapies for NMIBC. CEl-03'1 8Cts through a novelmech()nism of action to selectively kill bladder cancer cells. It does tl1is by targeting certain enzymes that are overexpressed in these cells. In clinical trials, CEl-03'1 WDS well tolemted with preJiminmy evidence of effic8cy 8gainst advanced cancers. However, efficacy was limited by poor ora! bioavailnbi lity. CEl-031 should demonstrate greater efficacy against NI\l1IBC, since it ViiI! be delivered by bladder instillation, thereby minimizing drug metabolism nnd protein binding issues. This project will investigate the effect of CEl-03" on bladder tumor cells and test for potential synergy in combination\Nith oUler drugs. A liquid formulation will be developed, which will be used to test CEl-031's efficacy in 8 mouse bladder C8ncer model. If these studies are sllccessful, a proof-of-concept clinical study of CEl-03'! in NMIBC patients viill be initiatedduring the Phase II SBIR project

Principal Investigator:

Graham Allaway
301-452-6452
GALLAWAY@CELEKPHARMA.COM

Business Contact:

Graham Allaway
301-452-6452
GALLAWAY@CELEKPHARMA.COM
Small Business Information at Submission:

CELEK PHARMACEUTICALS LLC
119 UPSHIRE CIR GAITHERSBURG, MD 20878-5215

EIN/Tax ID: 126428832
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No